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The extracellular L-glutamate (L-Glu) concentration is elevated in neuroinﬂammation, thereby causing
excitotoxicity. One of the mechanisms is down-regulation of astrocyte L-Glu transporters. Some anti-
depressants have anti-inﬂammatory effects. We therefore investigated effects of various antidepressants
on the down-regulation of astrocyte L-Glu transporters in the in vitro neuroinﬂammation model. Among
these antidepressants, only paroxetine was effective. We previously demonstrated that the down-
regulation of astrocyte L-Glu transporters was caused by L-Glu released from activated microglia. We
here clariﬁed that only paroxetine inhibited L-Glu release from microglia. This is the novel action of
paroxetine, which may bring advantages on the therapy of neuroinﬂammation.
© 2014 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Increasing evidence indicates that inﬂammatory processes play
important roles in the pathogenesis of many neurodegenerative
disorders (1e3). Under the neuroinﬂammatory conditions, it is
known that the extracellular concentration of L-glutamate (L-Glu)
and inﬂammatory mediators, such as proinﬂammatory cytokines,
prostaglandins, free radicals and complements are elevated (4). L-
Glu is one of the most abundant excitatory neurotransmitters in the
mammalian CNS. The released L-Glu is immediately uptaken by
astrocyte L-Glu transporters, GLAST (EAAT1 in human) and GLT-1
(EAAT2 in human), or sustained elevation of extracellular concen-
tration of L-Glu induce excitotoxicity. The impairment of the
astrocyte L-Glu transporters is reported in various neurological
disorders including Alzheimer's disease (5), Parkinson's diseases
(6) and amyotrophic lateral sclerosis (7). We found that the
expression level of L-Glu transporters in astrocytes of astrocyte-NS, central nervous system;
, L-glutamate; LPS, lipopoly-
X prinoceptor 4; RNA, ribo-
m dodecyl sulfate; SNRI,
selective serotonin reuptake
xytryptamine.
acological Society.
. Production and hosting by Elsemicroglia-neuron mixed culture was decreased in the in vitro
model of the early stage of inﬂammation in the previous study (8).
We clariﬁed the interaction between astrocytes and microglia un-
derlie the down-regulation of L-Glu transporters, i.e., activated
microglia release L-Glu and the resulting elevation of extracellular
L-Glu cause down-regulation of astrocytic L-Glu transporters. Some
antidepressants are known to have anti-inﬂammatory effects (9,
10). In this study, therefore, we investigated the effects of various
antidepressants on the decrease in the astrocytic L-Glu transporter
function in the early stage of inﬂammation and the contribution of
microglia to the effects.
Astrocyte-microglia-neuron mixed culture and microglia cul-
ture were performed according to the methods previously
described (8). Antidepressants and serotonin (5-HT) were dissolved
in PBS at 100 mM and 10 mM, respectively, and were diluted with
culture medium at the time of use. At 8 DIV, the astrocyte-
microglia-neuron mixed culture was treated with 10 ng/mL LPS
for 72 h. Antidepressants were applied from 1 h before to the end of
the LPS-treatment. Then the concentration of the L-Glu remaining
in the culture medium 30 min after changing extracellular con-
centration of L-Glu to 100 mM was measured. The measurement of
the extracellular L-Glu concentration in the medium was per-
formed according to the methods previously described (8). Real-
Time Quantitative RT-PCR, Western blotting, immunocytochem-
istry were also performed according to the methods previouslyvier B.V. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Effects of antidepressants on the decreased L-Glu transport activity under the inﬂammatory condition. AeE. Antidepressants were applied to the mixed culture from
1 h before to the end of the LPS-treatment (10 ng/ml, 72 h). L-Glu transport activity was quantiﬁed as the L-Glu remaining 30 min after changing the extracellular concentration to
100 mM. Paroxetine prevented the LPS-induced decrease in the L-Glu transport activity in a concentration-dependent manner (A). Fluvoxamine (B), sertraline (C), milnacipran (D),
and amitriptyline (E) had no effects. **: p < 0.01 vs. control group, #: p < 0.05 vs. LPS-treated group, Tukey's test following ANOVA (N¼ 6). F. Typical image of the microglia-
astrocyte-neuron mixed culture immunostained with cell type-speciﬁc markers (Iba1: microglia; GFAP: astrocytes; bIII tubulin: neurons). G, H. Effects of paroxetine on the
expression level of GLAST. Mixed cultures were treated with LPS (10 ng/ml) in the absence or presence of the paroxetine for 24 h (for mRNA level quantiﬁcation) or 72 h (for protein
level quantiﬁcation). The expression level of GLAST was quantiﬁed at mRNA level (G) and protein level (H). LPS (10 ng/ml) caused signiﬁcant decrease in GLAST mRNA level and
paroxetine signiﬁcantly prevented the decrease (G). LPS (10 ng/ml) caused signiﬁcant decrease in GLAST protein level and paroxetine almost completely prevented the decrease (H).
**: p< 0.01 vs. control group, ##: p < 0.01 vs. LPS-treated group, Tukey's test following ANOVA (N¼ 5).
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the presence or absence of antidepressants and the concentration
of L-Glu in the medium was measured. All sets of the experiments
were repeated in triplicate. All procedures described above were in
accordance with institutional guidelines.
In the previous report, we showed that the expression level of
astrocytic L-Glu transporters was decreased in the astrocyte-
microglia-neuron mixed culture in LPS (10 ng/ml, 72 h)-induced
inﬂammation model without cell death (8). We ﬁrst compared the
effects of various groups of antidepressants, i.e., selective serotonin
reuptake inhibitors (SSRIs) (paroxetine, ﬂuvoxamine, and sertra-
line), serotoninenorepinephrine reuptake inhibitor (SNRI) (milna-
cipran), and tricyclic antidepressant (TCA) (amitriptyline), on the
decrease in the astrocytic L-Glu transporter function in this
inﬂammation model. To quantify L-Glu transport activity, we
measured the concentration of L-Glu remaining 30 min after
changing the medium to the one containing 100 mM of L-Glu. In
each set of experiment, LPS-induced decrease in the L-Glu transportFig. 2. Relation of the effects of paroxetine on LPS-induced decrease in L-Glu transport
activity with its SSRI function and the direct effect on astrocytes. A. 72 h treatment
with 5-HT (1e100 mM) did not affect LPS-induced decrease in the L-Glu transport
activity. B. 72 h treatment with paroxetine (10e1000 nM) of astrocyte culture did not
affect its L-Glu transport activity. **: p< 0.01 vs. control group, Tukey's test following
ANOVA (N¼ 6).activity was stably reproduced (Fig. 1AeE). Among antidepressants,
only paroxetine prevented the LPS-induced decrease in L-Glu
transport activity (Fig.1A). The effect was concentration-dependent
and reached signiﬁcant at 1 mM. The other antidepressants had no
effects (Fig. 1BeE). Typical image of the astrocyte-microglia-neuron
mixed culture was shown in Fig. 1F. We have clariﬁed that LPS-
induced decrease in L-Glu transport activity was caused by the
decrease in the expression level of GLAST, a predominant L-Glu
transporter in the mixed culture, in both of mRNA and protein
levels (8). In this study, LPS-induced decreases in the expression of
GLAST, were reproduced at both of mRNA (28.8± 4.7% of the con-
trol) and protein (69.5± 4.7% of the control) levels (Fig. 1G, H). We
then examined the effects of paroxetine on the LPS-induced
decrease in the L-Glu transporter expression. Paroxetine signiﬁ-
cantly prevented the decreases at both of mRNA (28.8± 4.7 to
49.6± 3.3%; n ¼ 10) and protein (from 69.5± 4.7% to 91.0± 5.1%;
n¼ 5) levels (Fig. 1G, H). As is shown in Fig. 1, ﬂuvoxamine and
sertraline, the other SSRIs in this study, did not affect the decrease
in L-Glu transport activity, suggesting that paroxetine revealed the
effects through themechanisms independent of its inhibitory effect
on serotonin selective transporter. In support of this, LPS-induced
decrease in L-Glu transport activity was not changed by the
elevation of extracellular serotonin concentration (Fig. 2A). We also
conﬁrmed that paroxetine did not directly affect the L-Glu trans-
port activity of the astrocyte culture (Fig. 2B). In our previous
report, the down-regulation of GLAST in the inﬂammation model
was caused by the elevation of extracellular L-Glu released from
microglia (8). We therefore compared the effects of the antide-
pressants on LPS-induced L-Glu release from microglia. When
microglia culture was treated with 10 ng/ml LPS for 24 h in the
presence or absence of the antidepressants, only paroxetine sup-
pressed L-Glu release in a concentration-dependent manner
(Fig. 3A). The other antidepressants had no effects (Fig. 3BeE). We
conﬁrmed that paroxetine did not affect the microglial viability
until 10 mM by LDH assay (data not shown). These results strongly
suggest that the protective effect of paroxetine on the LPS-induced
down-regulation of astrocytic L-Glu transporters was caused by the
suppression of L-Glu release from microglia.
The shape of microglia in the mixed culture was dramatically
changed to amoeboid type by LPS and this morphological change
was remarkably suppressed by paroxetine (unpublished observa-
tion). This suggests that paroxetine does not only suppress L-Glu
release from microglia alone but also microglial activation. To
demonstrate this possibility, the effect of paroxetine on the
microglial activation is needed to be conﬁrmed using multiple
parameters. Because SSRIs have diverse chemical structures despite
a common mode of action of 5-HT function (11), it is possible that
paroxetine revealed the effects through interaction with
paroxetine-speciﬁc target molecules. Because paroxetine exhibited
the powerful inhibition of calcium inﬂux via P2X4 receptors (12),
P2X4 receptor is one of the most probable candidate molecules. The
expression level of P2X4 receptor in microglia is up-regulated in
inﬂammatory pain model in spinal cord and is thought to be
important for microglial inﬂammatory responses (13). MAPK
signaling molecules (14) and GABA(B) receptor (15) are possibly
involved in the paroxetine-speciﬁc effects as well. The effective
concentration of paroxetine to reduce L-Glu release was 1 mM. Ac-
cording to the attached documents of paroxetine (http://www.info.
pmda.go.jp/), intracerebral concentration of paroxetine reaches
77 nM by 25 mg/day-repeated administration. It is therefore un-
likely that paroxetine affects astrocyte L-Glu transporters and
microglia by the general dosage of SSRI. For clinical application of
our present ﬁndings, further investigation concerning application
period and dosage is needed.
Fig. 3. Effects of antidepressants on the L-Glu release from microglia under the inﬂammatory condition. In each set of experiment, antidepressants were applied to the mixed
culture from 1 h before to the end of the LPS-treatment (10 ng/ml, 24 h). The extracellular concentration of L-Glu was quantiﬁed. Paroxetine prevented the LPS-induced L-Glu
release from microglia in a concentration-dependent manner (A). Fluvoxamine (B), sertraline (C), milnacipran (D), and amitriptyline (E) had no effects on LPS-induced L-Glu release
from microglia. **: p < 0.01 vs. control group, #: p < 0.05 vs. LPS-treated group, Tukey's test following ANOVA (N¼ 6).
K. Fujimori et al. / Journal of Pharmacological Sciences 127 (2015) 145e149148In conclusion, we found that paroxetine inhibit the L-Glu release
from activatedmicroglia and prevent down-regulation of astrocytic
L-Glu transporters in the early stage of neuroinﬂammation. This is
the novel pharmacological effect of paroxetine, which may bring
advantages on the therapy of the disease associated with
neuroinﬂammation.
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